MeSH term
Frequency | Condition_Probility | *Antigens, CD | 34 | 4.0 |
Cell Differentiation | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Humans | 84 | 0.0 |
Immunoenzyme Techniques | 4 | 0.0 |
Male | 47 | 0.0 |
Membrane Glycoproteins/*metabolism | 7 | 1.0 |
Neoplasm Staging | 10 | 0.0 |
Prostatic Hyperplasia/*metabolism | 2 | 4.0 |
Prostatic Neoplasms/*metabolism/pathology | 2 | 2.0 |
*Proto-Oncogene Proteins | 65 | 3.0 |
Research Support, Non-U.S. Gov't | 49 | 0.0 |
Antigens, CD/*biosynthesis | 2 | 1.0 |
Disease Progression | 9 | 0.0 |
Down-Regulation | 15 | 0.0 |
Female | 33 | 0.0 |
Immunohistochemistry | 19 | 0.0 |
Membrane Glycoproteins/*biosynthesis | 4 | 4.0 |
Neoplasm Metastasis | 13 | 1.0 |
Aged | 15 | 0.0 |
Alleles | 3 | 0.0 |
Azacitidine/*analogs & derivatives/pharmacology | 2 | 2.0 |
Chromosomes, Human, Pair 11/genetics | 2 | 0.0 |
Comparative Study | 9 | 0.0 |
DNA Mutational Analysis | 3 | 0.0 |
DNA, Neoplasm/genetics | 4 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Epithelium/metabolism | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 12 | 0.0 |
Membrane Glycoproteins/*genetics/*metabolism | 2 | 8.0 |
Middle Aged | 21 | 0.0 |
Neoplasm Metastasis/*genetics | 10 | 16.0 |
Polymerase Chain Reaction | 8 | 0.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
Protein p53/genetics/metabolism | 2 | 2.0 |
RNA, Messenger/metabolism | 9 | 0.0 |
English Abstract | 6 | 0.0 |
Mice | 13 | 0.0 |
Mice, Nude | 7 | 0.0 |
*Neoplasm Proteins | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 22 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 8 | 0.0 |
Transfection | 8 | 0.0 |
Amino Acid Sequence | 4 | 0.0 |
*Genes, Tumor Suppressor | 21 | 2.0 |
Molecular Sequence Data | 10 | 0.0 |
Neoplasm Metastasis/genetics | 5 | 12.0 |
Prostatic Neoplasms/*genetics/metabolism/pathology | 3 | 10.0 |
Protein Conformation | 2 | 0.0 |
Membrane Glycoproteins/*biosynthesis/genetics | 6 | 10.0 |
Mutation | 4 | 0.0 |
Prostatic Neoplasms/*genetics/pathology | 5 | 6.0 |
Tumor Cells, Cultured | 24 | 0.0 |
*Gene Expression Regulation, Neoplastic | 7 | 0.0 |
Membrane Glycoproteins/*genetics/metabolism | 6 | 8.0 |
Reference Values | 5 | 0.0 |
Animals | 20 | 0.0 |
Cell Adhesion | 3 | 0.0 |
Mice, SCID | 3 | 0.0 |
Neoplasm Circulating Cells | 2 | 7.0 |
Prognosis | 11 | 0.0 |
Protein p53/biosynthesis/genetics | 2 | 4.0 |
Survival Rate | 3 | 0.0 |
Blotting, Western | 4 | 0.0 |
*Gene Expression | 3 | 0.0 |
*Neoplasm Metastasis | 3 | 3.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Adenocarcinoma/genetics/*pathology | 2 | 9.0 |
Base Sequence | 12 | 0.0 |
Membrane Glycoproteins/biosynthesis/*genetics | 3 | 9.0 |
Prostatic Neoplasms/genetics/*pathology | 2 | 10.0 |
Cell Division/physiology | 2 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Genes, Tumor Suppressor | 7 | 0.0 |
Cell Line, Tumor | 9 | 0.0 |
DNA Primers | 3 | 0.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 2 | 0.0 |
Antigens, Surface | 2 | 3.0 |
Cohort Studies | 2 | 0.0 |
Disease-Free Survival | 2 | 0.0 |
Adolescent | 2 | 0.0 |
Adult | 13 | 0.0 |
Blotting, Northern | 6 | 0.0 |
In Situ Hybridization | 10 | 0.0 |
Membrane Glycoproteins/*genetics | 17 | 3.0 |
Pancreatic Neoplasms/*genetics/pathology | 2 | 5.0 |
RNA, Messenger/analysis | 5 | 0.0 |
Lymphatic Metastasis | 3 | 0.0 |
Neoplasm Transplantation | 3 | 0.0 |
Rats | 7 | 0.0 |
Prostatic Neoplasms/*genetics | 4 | 2.0 |
Antigens, CD/*metabolism | 6 | 0.0 |
Neoplasm Proteins/*metabolism | 3 | 0.0 |
Protein p53/*metabolism | 4 | 0.0 |
Antigens, CD/*biosynthesis/genetics | 3 | 5.0 |
Chromosome Mapping | 5 | 0.0 |
Chromosomes, Human, Pair 11 | 2 | 0.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
Lymphatic Metastasis/genetics | 4 | 14.0 |
Gene Expression | 6 | 0.0 |
Membrane Glycoproteins/genetics/*metabolism | 2 | 1.0 |
*Membrane Glycoproteins | 4 | 0.0 |
Neoplasm Invasiveness | 9 | 0.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Antigens, CD/*genetics/metabolism | 3 | 6.0 |
Proto-Oncogene Proteins c-jun/genetics/*metabolism | 2 | 6.0 |
Transcription Factor AP-1/metabolism | 2 | 0.0 |
Antigens, CD/*genetics | 10 | 3.0 |
Carcinoma/*genetics/pathology | 2 | 3.0 |
Genes, Tumor Suppressor/*genetics | 4 | 1.0 |
Anticarcinogenic Agents | 2 | 33.0 |
Neoplasm Metastasis/*prevention & control | 3 | 25.0 |
Protein p53/metabolism | 2 | 0.0 |
RNA, Messenger/genetics | 5 | 0.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
Retinoblastoma Protein/metabolism | 2 | 0.0 |
Tumor Markers, Biological/*metabolism | 2 | 0.0 |
Cell Division | 2 | 0.0 |
Up-Regulation | 2 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Aged, 80 and over | 5 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Carcinoma, Squamous Cell/*metabolism | 2 | 1.0 |
Phenotype | 2 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 3 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Prostate/metabolism | 4 | 5.0 |
*Genes, Tumor Suppressor/physiology | 2 | 40.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
Binding Sites/genetics | 2 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Cells, Cultured | 2 | 0.0 |
*Down-Regulation | 2 | 0.0 |
Cell Aggregation/genetics | 3 | 60.0 |
Transcription, Genetic | 2 | 0.0 |
Adenocarcinoma/*metabolism | 2 | 2.0 |
Paraffin Embedding | 2 | 0.0 |
Genetic Markers | 2 | 0.0 |
Cell Division/genetics | 3 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Adenocarcinoma/*genetics/pathology | 2 | 2.0 |
*Chromosome Mapping | 2 | 0.0 |
*Chromosomes, Human, Pair 11 | 2 | 0.0 |
Chromosome Aberrations | 2 | 0.0 |
Tumor Markers, Biological | 3 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Genes, Tumor Suppressor/*physiology | 4 | 3.0 |
Membrane Glycoproteins/*genetics/physiology | 2 | 12.0 |
Neoplasm Invasiveness/pathology | 2 | 3.0 |
